Fritextsökning
Innehållstyper
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...
-
Anna-Karin Maltais ny vetenskaplig chef hos XNK Therapeutics
Det svenska immunterapibolaget XNK Therapeutics tar in Anna-Karin Maltais som CSO. Hon tillträder tjänsten den 17 oktober.
-
Astra Zeneca nådde inte mål i lungcancerstudie
-
Integrated solutions for liquid handling
Greater efficiency for manufacturers in laboratory automation and many other industries
-
Lundbeck behind the first EU-approved intravenous migraine treatment
A preventive, intravenous treatment for migraines has been approved in the EU for the first time.
-
From the sea of Åland to a self-test for lithium
Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be av...
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...
-
Search ledde till drömrekrytering för Intertek
Det har nu gått över ett år sen – men vi på Poolia är fortfarande stolta över det arbete som gjorde att vi fann Christopher till Interteks nya roll som affärsom...
-
“Everyone is screaming for talent”
Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Hor...
-
Tyskt bioteknikföretag utvecklar test för apkoppsviruset
R-Biopharm har tagit fram ett PCR-test för att påvisa apkoppsvirus. Testet lanseras om några veckor.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...
-
On the hunt for high throughput diagnostics
Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...
-
Event: Drug Development – Serendipity or Science
Drug development is a challenging journey, we will discuss questions you may not even consider asking. SDS and Medicon Village welcome you to an engaging afternoon.
-
Column: ”We need to exploit the benefits of the regulations“
You don’t need to search long on the Internet to find lists of the most innovative countries with Sweden ranking at the top. Sweden generally offers good condit...
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...
-
Har du också sett fördelen med IO-Link?
SMC erbjuder ett komplett sortiment från master till givare.
-
"Are we doing business the wrong way around in the Life Science Sector?"
For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job...
-
Marie Gårdmark: Do EMA and FDA talk to each other?
Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...
-
Giulia Gaudenzi: Innovation for good
"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...
-
Abigo nyanställer
Life science-företaget Abigo har anställt en ny kommunikationschef och en ny risk and quality specialist.
-
Column: Repurposing as a golden ticket to approval
"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...